Caris Life Sciences, Inc. research snapshot
CAI AI stock analysis currently reads Caris Life Sciences as an AI-driven precision medicine company with rapid revenue growth, expanding margins, and a strong cash position. The analysis is not a certain price prediction. At the July 12, 2026 cutoff, the latest verified close used here was $16.99, market capitalization was about $4.80 billion, and the main question was whether sustained revenue growth (97% YoY in FY2025, 79% in Q1 2026), operating income profitability, and the large precision oncology TAM can overcome the stock being 60% below its IPO high, unanswered GAAP profitability, and market skepticism about growth stock valuations. This is informational research and not investment advice.
Current price
$16.99
Market cap
$4.80 billion
AI score
51 / 100
Rating
Growth stage with improving financials, high volatility
Trend status
Down 60% from IPO high, trading near 52-week lows with improving fundamentals
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Caris Life Sciences provides precision medicine solutions including tissue-based and blood-based comprehensive genomic profiling for cancer patients. The business model benefits from recurring testing volumes, biopharma partnerships, and an expanding menu of AI-powered diagnostic products. | Medium |
| Moat | The moat comes from proprietary molecular profiling databases (one of the largest clinico-genomic datasets), AI-powered analysis platforms (GPSai, MI Profile), and established relationships with biopharma companies. However, competitors like Foundation Medicine, Guardant Health, and Tempus have similar assets. | Medium |
| Management | Founder and CEO David D. Halbert has led the company since 2008 through its growth from a pathology lab to an AI-driven precision medicine company. The IPO in 2025 raised significant capital. Management has demonstrated execution on revenue growth and margin expansion. Key-person risk exists given founder-led structure. | Medium |
| Financial trend | Revenue grew from $306M (FY2023) to $812M (FY2025), a 2.7x increase in two years. Gross margin expanded from 29% to 66% in the same period. Operating income turned positive at $45M in FY2025. Net loss narrowed from -$341M to -$68M. Cash position is strong at $798M against $379M in total debt. | Medium-high |
| Valuation | At $16.99, CAI trades at 5.9x trailing revenue and 8.3x book value. No P/E is applicable due to GAAP losses. The revenue multiple is moderate for a company growing at nearly 100% but reflects market skepticism about sustainability. Enterprise value of ~$4.0B represents about 4.9x FY2025 revenue. | Medium |
| Technical trend | CAI is trading near its 52-week low of $14.19, far below the all-time high of $42.50 from August 2025. The stock has been in a sustained downtrend since its IPO pop, with lower highs and lower lows. Recent price action shows potential basing near the $14 to $17 range. | Medium |
| Risk level | Elevated. Key risks include competitive pressure in precision oncology, reimbursement uncertainty, dependence on biopharma partnership revenue, stock volatility (beta 1.85), limited public trading history (IPO June 2025), and the risk that rapid revenue growth decelerates as the base expands. | High |
| AI confidence | Medium confidence for the business model understanding, financial filings, revenue growth trajectory, cash position, and valuation math. Lower confidence for future revenue growth rates, margin targets, competitive positioning evolution, and stock price scenarios given the brief public track record. | Medium data confidence |
| Investment certainty | Low. Caris Life Sciences offers a compelling growth story with improving financials, but the stock has lost 60% of its value since the IPO high, suggesting significant market skepticism. The outcome depends on sustained revenue growth, path to sustained GAAP profitability, and competitive dynamics in precision oncology. | Low |
CAI AI stock forecast
The CAI AI stock forecast uses scenario ranges around the $16.99 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires sustained 50%+ revenue growth, continued margin expansion to GAAP profitability, and market re-rating. The base case assumes growth decelerates to 30-40% with steady margin improvement. The bearish case assumes competition intensifies, growth slows sharply, and profitability remains elusive.
$32 to $42
More likely if Caris maintains 50%+ revenue growth driven by molecular profiling volume expansion, biopharma partnerships deepen, gross margins reach 70%+, GAAP profitability is achieved within 12 months, and the market re-rates the stock toward 6-8x forward revenue.
$14 to $24
More likely if revenue growth decelerates to 30-40%, operating margins expand gradually but GAAP profitability remains 12-18 months away, competitive pressure from Foundation Medicine and Tempus limits market share gains, and the stock trades near 3-5x trailing revenue.
$8 to $13
More likely if revenue growth drops below 25%, competitive pressure intensifies, reimbursement changes reduce testing volumes, cash burn accelerates, or the company needs to raise additional capital to fund operations.
CAI AI technical analysis
CAI AI technical analysis starts from the approximately $16.99 recent trading area used for this July 12 static page. Public technical sources showed the stock near its 52-week low of $14.19 and far below the all-time high of $42.50. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $16.99 | Latest verified close used for this page as of the July 12, 2026 data cutoff. |
| Near support | $14.00 to $15.00 | Support area near the 52-week low of $14.19 and the IPO after-lockup low zone reported by public technical sources. |
| Secondary support | $12.00 to $13.50 | If the $14 support breaks, the next demand zone would be near $12 to $13.50. A break below would suggest structural problems with the growth thesis. |
| Near resistance | $20.00 to $22.00 | The first overhead resistance zone. A breakout above this level with volume would suggest momentum is shifting. |
| Key resistance | $28.00 to $32.00 | The area between the 50% Fibonacci retracement from the all-time high and the post-IPO breakdown level. A move above would signal a potential trend reversal. |
| 50-day moving average | Approximately $18.50 to $20.00 | Public technical sources showed CAI trading near or slightly below its 50-day moving average around the cutoff. |
| 200-day moving average | Approximately $26.00 to $30.00 | Public technical sources showed CAI well below its 200-day moving average, confirming the long-term downtrend is still in effect. |
| Momentum | RSI oversold, MACD bearish | RSI was near oversold territory, while MACD remained bearish. Oversold conditions alone are not a buy signal without a catalyst. |
| Volume | About 600,000 to 800,000 shares daily | Trading volume was moderate. Volume spikes on up days would be a more constructive sign for potential reversal. |
| Volatility | Beta 1.85, ATR about $1.20 to $1.50 | The beta is well above market average, indicating the stock is about 85% more volatile than the market. Position sizing must account for this. |
| Invalidation | Close below $14.00, then $12.00 | A close below $14.19 (52-week low) would suggest a new leg down. A break below $12.00 would challenge the entire growth investment thesis. |
CAI AI trading strategy
The CAI AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels. Given CAI is a high-growth, high-volatility stock near its lows, position size should reflect elevated uncertainty and the stock being in a downtrend.
Wait for CAI to establish a higher low above $16 and break through the $20 to $22 resistance zone with improving volume and a positive catalyst (earnings beat, guidance raise, major partnership announcement). Momentum traders should wait for the 50-day moving average to slope upward before committing.
A failed breakout, low-volume move above resistance, or daily close back below $16 should reduce confidence. The downtrend from $42.50 is intact until the stock reclaims the 200-day moving average.
If CAI pulls back toward the $14 to $15 support zone without a thesis break and shows price stabilization with declining volume, a cautious mean-reversion approach could be considered. However, this is a high-risk approach given the stock is in a sustained downtrend.
Do not average down solely because the stock is cheap. Define maximum position loss. Mean-reversion in a downtrend is inherently risky. Wait for the next quarterly earnings before adding to any position.
Track quarterly revenue growth rate, molecular profiling test volumes, gross margin trajectory, operating margin progression, cash burn rate, and management guidance. Key milestones include achieving GAAP net income profitability and maintaining 30%+ revenue growth.
Lower the rating if revenue growth decelerates below 25%, gross margins compress, operating losses expand, or management signals a need for dilutive capital raising. Monitor insider buying/selling patterns given the founder-led structure.
Investment research summary
Caris Life Sciences provides comprehensive genomic profiling (CGP) tests and AI-powered precision medicine solutions for cancer patients. The business model generates revenue from molecular profiling services (tissue-based MI Profile and blood-based Caris Assure) sold to oncologists, hospitals, and biopharma partners. The AI platform (GPSai) analyzes clinico-genomic data to guide treatment decisions and accelerate drug development.
The moat stems from Caris' large proprietary clinico-genomic database accumulated over 15+ years, AI-powered analysis tools, relationships with major biopharma companies for clinical trial matching, and CLIA-certified laboratory infrastructure. However, competitors like Foundation Medicine (Roche), Guardant Health, and Tempus have similar or larger datasets and resources.
The thesis can fail if: (1) revenue growth decelerates sharply as the base expands and competition increases; (2) gross margins compress due to pricing pressure from payers or competitors; (3) GAAP profitability remains elusive and the company needs dilutive capital; (4) a competitor achieves superior AI-driven diagnostic accuracy; or (5) Medicare/private payer reimbursement changes reduce testing volumes.
Founder David D. Halbert has led Caris since 2008, demonstrating long-term vision and execution. Management successfully grew the company from a pathology lab to a NASDAQ-listed AI precision medicine company with $812M in revenue. The IPO raised substantial capital, positioning the company for continued investment. However, the founder-led structure creates key-person risk, and management has yet to demonstrate performance in a public company environment through a full market cycle.
Precision oncology is experiencing a secular growth trend driven by expanding biomarker research, FDA approvals for targeted therapies, increasing adoption of comprehensive genomic profiling, and AI integration into diagnostic workflows. The global precision medicine market is estimated at $100B+ and growing. Caris is positioned in the high-growth molecular diagnostics segment.
At roughly $16.99, CAI trades at 5.9x trailing revenue and 8.3x book value with negative GAAP earnings. The enterprise value of $4.0B represents about 4.9x FY2025 revenue. The margin of safety is limited because the stock already prices in significant growth. If revenue growth drops below 25% or GAAP profitability remains years away, the current valuation would not provide much downside protection.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| CAI price | $16.99 approximate close on July 10, 2026 | Barchart and TradingView quote snapshots | July 12, 2026 |
| Market capitalization | $4.80 billion, verified as $16.99 x 282,580,000 shares | financial_rigor.py market cap verification and Barchart shares outstanding | July 12, 2026 |
| FY2025 revenue | $812.03 million | Barchart annual income statement and TradingView financials overview | July 12, 2026 |
| FY2025 net income | -$68.09 million GAAP net loss | Barchart annual income statement (net income from continuing operations) | July 12, 2026 |
| Gross margin | 66.4% in FY2025, expanding from 29.2% in FY2023 | Calculated from Barchart gross profit ($539M) and revenue ($812M) data | July 12, 2026 |
| Operating income | +$45.1 million in FY2025, first positive year | Barchart annual income statement operating income line | July 12, 2026 |
| Cash and equivalents | $797.8 million at December 31, 2025 | Barchart annual balance sheet | July 12, 2026 |
| Total debt | $379.0 million at December 31, 2025 | Barchart annual balance sheet (short + long term debt) | July 12, 2026 |
| Revenue growth Q1 2026 | 79% year-over-year | Caris Life Sciences Q1 2026 earnings release | July 12, 2026 |
| P/S ratio | 5.9x trailing revenue | financial_rigor.py valuation verification | July 12, 2026 |
| 52-week range | $14.19 to $42.50 (IPO high) | Barchart and TradingView 52-week price range | July 12, 2026 |
This CAI AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 12, 2026 and can be wrong. Past financial performance and revenue growth do not guarantee future results. Caris Life Sciences recently IPO'd in June 2025 and has a limited public trading history. The stock is highly volatile (beta 1.85) and may lose value significantly.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
